Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells
However, Phase 1b/2a results in 125 patients must be confirmed in large Phase 3 trials
Their neglect has often resulted from early adverse events attributable to poor pharmacokinetic design, incomplete receptor mapping, or the absence of enabling technologies now considered routine, such as long-acting peptide conjugation, tissue-selective targeting, and signal-bias optimization
SLC, solute carrier family
It exists purely to establish GI tolerance
Bella AJ, Beasley KA, Obied A et al: Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique